feksofenadin cipla 120 mg
cipla europe nv - feksofenadinhydroklorid - tablett, filmdrasjert - 120 mg
feksofenadin cipla 180 mg
cipla europe nv - feksofenadinhydroklorid - tablett, filmdrasjert - 180 mg
altifex 120 mg
orifarm generics (3) - feksofenadinhydroklorid - tablett, filmdrasjert - 120 mg
telfast 180 mg
opella healthcare france sas - feksofenadinhydroklorid - tablett, filmdrasjert - 180 mg
telfast 120 mg
opella healthcare france sas - feksofenadinhydroklorid - tablett, filmdrasjert - 120 mg
hypericum stada -
stada arzneimittel ag - prikkperikum - kapsel, hard
rimactazid 150 mg / 75 mg
sandoz - københavn - rifampicin / isoniazid - tablett, filmdrasjert - 150 mg / 75 mg
rimstar
sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg
orkambi
vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystisk fibrose - andre åndedrettsprodukter - orkambi tabletter er angitt for behandling av cystisk fibrose (cf) hos pasienter i alderen 6 år og eldre som er homozygote for f508del-mutasjon i cftr-genet. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.